相关实验视频

Updated: Jul 27, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

设计,合成,对接,MD模拟和烯[2,3-3-]的抗扩散评估

Eman A Sobh¹, Mohammed A Dahab², Eslam B Elkaeed³

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt.

Journal of enzyme inhibition and medicinal chemistry

|June 8, 2023

概括

研究人员开发了新[2,3-d]金胺化合物作为抗癌剂. 化合物5b有效地抑制了癌细胞,诱导了亡,并显示出有利的安全性,显示出作为主要抗增殖药物候选人的前景.

科学领域:

药用化学医学化学
分子生物学分子生物学
计算化学计算化学

背景情况:

表皮生长因子受体 (EGFR) 是癌症治疗的关键标.
开发具有提高疗效和安全性的新型EGFR抑制剂至关重要.
提[2,3-d]胺基支架为药物设计提供了一个有前途的结构基础.

研究的目的:

设计,合成和评估新[2,3-d]金胺衍生物作为向EGFR的潜在抗癌剂.
确定最强效的抗扩散化合物并评估其作用机制.
通过计算研究来评估化合物的安全性和药物相似性.

主要方法:

提[2,3-d]胺衍生物的合成.
使用MCF-7和A549癌细胞系进行体外抗增殖试验.
在A549细胞中诱导亡和细胞周期分析.
基因表达分析 (BAX,Bcl-2).
对EGFR进行分子对接和分子动力学 (MD) 模拟.
在 silico ADMET (吸收,分布,新陈代谢,分泌,毒性) 预测.

主要成果:

化合物5b对EGFR野生类型 (EGFRWT) 和EGFR T790M突变物表现出强大的抑制作用.
化合物5b在正常的WI-38细胞中显示出高于erlotinib的安全性.
5b诱导了早期和晚期的亡,并阻止了A549细胞周期的进展.
基因表达分析显示了BAX的显著上调和BCL-2的下调.
分子建模证实了有利的结合模式和与EGFR的稳定相互作用.

结论:

化合物5b是一种新[2,3-d]胺衍生物,显示出作为抗癌化合物的显著潜力.
它的疗效,安全性和作用机制需要进一步研究,以开发治疗方法.
计算研究支持其类似药物的特性和临床应用的潜力.

关键词:

防止扩散的措施.作为EGFR抑制剂的使用.模拟MDMD的模拟灭症 (apoptosis) 是一种死亡的过程.乙烯基[2,3-d] 皮里米丁.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...